...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Digestive Diseases and Sciences >Autoantibodies as Prognostic Markers in Autoimmune Liver Disease
【24h】

Autoantibodies as Prognostic Markers in Autoimmune Liver Disease

机译：自身抗体作为自身免疫性肝病的预后标记

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Certain autoantibodies in autoimmune liver disease have prognostic implications that are under-utilized and under-developed. The goals of this review are to indicate progress in characterizing the autoantibodies with prognostic connotations and to indicate the feasibility and importance of discovering other markers. Prime source and review articles in English were selected by a Medline search through 2010. Antibodies to soluble liver antigen, actin, liver cytosol type 1, asialoglycoprotein receptor, chromatin, cyclic citrullinated peptide, and uridine glucuronosyltransferases have been associated with the occurrence, severity, and progression of autoimmune hepatitis, and antibodies to Sp100, gp210, and centromere have had similar implications in primary biliary cirrhosis. Antibodies to soluble liver antigen have shown the most promise in autoimmune hepatitis as they have been associated with severe histological changes, long durations of treatment, relapse after drug withdrawal, and high frequency of liver failure. Antibodies to the nuclear rim pore protein, gp210, have shown the most promise in primary biliary cirrhosis as they have been associated with severe interface hepatitis, lobular inflammation, and progression to liver failure. The major limitations of the autoantibodies have been their lack of standardized assays, low negative predictabilities, and fluctuating levels. Performance parameters will improve as critical pathogenic pathways, comprehensive testing batteries, and standardized assays through international exchange workshops are developed. Progress has been made in identifying the serological markers of prognosis in autoimmune liver disease, and they promise to reflect critical disease mechanisms and enhance patient management.
机译：自身免疫性肝病中的某些自身抗体具有未充分利用和开发不足的预后影响。这篇综述的目的是指出表征具有预后意义的自身抗体的进展，并指出发现其他标记物的可行性和重要性。在2010年之前通过Medline搜索选择了英文的主要来源和评论文章。与可溶性肝抗原，肌动蛋白，1型肝细胞溶质，去唾液酸糖蛋白受体，染色质，环瓜氨酸肽和尿苷葡萄糖醛糖基转移酶的抗体相关，其发生率，严重程度，自身免疫性肝炎的发展和进展，以及针对Sp100，gp210和着丝粒的抗体在原发性胆汁性肝硬化中具有相似的含义。可溶性肝抗原的抗体在自身免疫性肝炎中显示出最有希望的前景，因为它们与严重的组织学改变，长时间的治疗，停药后复发以及肝衰竭的高发率有关。核边缘孔蛋白gp210的抗体在原发性胆汁性肝硬化中显示出最有希望的前景，因为它们与严重的界面肝炎，小叶发炎和进展为肝衰竭有关。自身抗体的主要局限性在于它们缺乏标准化的检测方法，较低的阴性可预测性以及波动的水平。性能参数将随着关键的病原体途径，综合测试电池和通过国际交流研讨会的标准化测定方法的开发而提高。在确定自身免疫性肝病预后的血清学指标方面已取得进展，它们有望反映出关键的疾病机制并加强患者管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号